SPOTLIGHT -
Dr. Bloom Explains Situations Requiring HER2 Retesting
Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Read More
Dr. Bloom Compares HER2 Screening Assays
Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
